Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is positioned well for long-term success as a biotechnology company, with a promising pipeline and potential for accelerated market entry. Solid financials and future catalysts, such as the upcoming readout of EYPT's wAMD trials, also support a positive outlook for the company's stock. However, potential label limitations for their pipeline products and competition from other biotechs in the space should be closely monitored for any impact on commercial success.

Bears say

Ocular Therapeutix is facing challenges in its clinical development and commercialization of its leading product candidate, Axpaxli, which is its main value driver. The success of Axpaxli relies on its acceptance by healthcare providers and patients, as well as reimbursement and coverage by payers. There are also risks associated with the clinical trials and competition from established pharmaceutical companies. In addition, market and economic factors may also affect the commercial success of Axpaxli. However, the company has shown positive results in its pivotal trial for wAMD and is expecting to report results for another pivotal trial in 1Q27. Ocular Therapeutix also faces competition from EYPT in the long-acting TKI market for wAMD, but there is potential for success for both companies in the $10 billion market.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.